Conference Call Scheduled for Thursday, June 6 at 5:30am
PT/8:30am ET
SAN
DIEGO, June 5, 2024 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the
grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20
product obtained from Halozyme's ENHANZE® manufacturing methods
that the Company provides to its current and future licensees. The
new patent is licensed under all of Halozyme's ENHANZE® licenses.
It will be validated in 37 European countries and expires on
March 6, 2029.
"This new European patent for ENHANZE further strengthens our
robust patent estate and extends the durability of our portfolio,"
said Dr. Helen Torley, president and
chief executive officer of Halozyme. "We are pleased to be able to
maintain the original royalty rate for DARZALEX SC in Europe through March
2029 based on this new patent."
Under the terms of Halozyme's ENHANZE® license with Janssen, the
newly granted patent prevents the reduction in the royalty rate on
sales of DARZALEX® SC in the European countries where it is
validated until the patent expires. The new patent is not expected
to have any impact to royalties under other ENHANZE® licenses with
an issued or pending collaboration patent, as current royalty rates
for these licenses are already expected to extend beyond expiration
of the new patent.
Webcast and Conference Call
Halozyme will discuss the new European patent and provide an
update to its 2024 financial guidance and 5-year financial outlook
on a conference call tomorrow, Thursday,
June 6 at 5:30am
PT/8:30am ET. The call will be
webcast live through the "Investors" section of Halozyme's
corporate website and a recording will be made available following
the completion of the call. To access the webcast and presentation,
please visit ir.halozyme.com.
The call may also be accessed with the dial-in information
below:
Participant Toll-Free Number: 888-632-3384
Participant Direct/International Number: 785-424-1794
Conference ID: HALO0624
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive
solutions to improve patient experiences and outcomes for emerging
and established therapies. As the innovators of ENHANZE® drug
delivery technology with the proprietary enzyme rHuPH20, Halozyme's
commercially-validated solution is used to facilitate the
subcutaneous delivery of injected drugs and fluids, with the goal
of reducing treatment burden for patients. Having touched more than
800,000 patient lives in post-marketing use in seven commercialized
products across more than 100 global markets, Halozyme has licensed
its ENHANZE® technology to leading pharmaceutical and biotechnology
companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli
Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai
Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for
itself or with partners, drug-device combination products using its
advanced auto-injector technologies that are designed to provide
commercial or functional advantages such as improved convenience,
reliability and tolerability, and enhanced patient comfort and
adherence. The Company has two commercial proprietary products,
Hylenex® and XYOSTED®, partnered commercial products and ongoing
product development programs with several pharmaceutical companies
including Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme is headquartered in San
Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations
facility.
For more information visit www.halozyme.com and connect with us
on LinkedIn and Twitter.
Safe Harbor Statement
In addition to historical information, the statements set forth
in this press release include forward-looking statements including,
without limitation, statements concerning the recent grant of
Halozyme's European Patent No. 4269578 covering Halozyme's
ENHANZE® drug delivery technology rHuPH20 product including the
expected validation of the patent in thirty-seven European
countries, the future expected expiration date of the patent, the
expected impact the patent will have on Halozyme's current and
future ENHANZE® licenses, including the expected prevention of the
reduction in the royalty rate Halozyme receives under the Janssen
license on sales of products co-formulated with ENHANZE® in the
European countries where the patent is validated.
These forward-looking statements are typically, but not always,
identified through use of the words "believe," "expected,"
"pending," "enable," "may," "will," "could," "intends," "estimate,"
"anticipate," "plan," "predict," "probable," "potential,"
"possible," "should," "continue," and other words of similar
meaning and involve risk and uncertainties that could cause actual
results to differ materially from those in the forward-looking
statements. Actual results could differ materially from the
expectations contained in these forward-looking statements as a
result of several factors, including unexpected results or delays
in the validation of the recently issued European patent in
European countries and termination of the European patent prior to
the expected date of expiration. These and other factors that may
result in differences are discussed in greater detail
in Halozyme's most recent Annual Report on Form 10-K and
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission. Except as required by law, Halozyme
undertakes no duty or obligation to update forward-looking
statements to reflect events after the date of this press
release.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-announces-issuance-of-new-european-patent-for-enhanze-drug-delivery-platform-302165251.html
SOURCE Halozyme Therapeutics, Inc.